Tumor Antigen Identification for Cancer Immunotherapy Publisher



Balibegloo M^{1, 2} ; Keshavarzfathi M^{2, 3} ; Rezaei N^{1, 4, 5}
Source: Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition Published:2020

Abstract

The immune system has shown to be capable of acting against malignant cells, in which recognizing the tumor antigen is an essential step. Tumor antigens are different in structure, expression and presentation, origin, immunogenicity, etc. Thus, it is very important to identify the antigens with favored properties. Several techniques have been developed for tumor antigen identification; the major two categories are indirect immunology based on algorithms predicting the HLA-peptide binding affinity ranking the candidate antigens which will further be validated versus direct HLA peptidomics approach which derives samples, isolates HLA-peptide complex, and determines the sequence of the peptide as a tumor antigen. Better antitumor immunotherapeutics such as personalized medicine, efficient adoptive T-cell therapy, immune vaccines, etc. will be provided through the development of more advanced antigen identification protocols. © Springer Nature Switzerland AG 2015, 2021. All rights reserved.